See the DrugPatentWatch profile for Nitrofurantoin
The drug Nitrofurantoin mono mcr, also known as macr-controlled nitrofurantoin, is a form of nitrofurantoin designed for urinary tract infection (UTI) treatment [1].
How does macr-controlled nitrofurantoin work?
Macrocrystal (macr) controlled-release nitrofurantoin releases the active drug gradually over time. This sustained release mechanism helps maintain therapeutic levels of nitrofurantoin in the urinary tract, potentially leading to improved efficacy and tolerability compared to immediate-release formulations [1].
What are the benefits of macr-controlled nitrofurantoin?
The macrocrystal formulation aims to provide a steady concentration of nitrofurantoin in the urine, which is crucial for effectively combating bacterial infections. This controlled release may also reduce the frequency of dosing and potentially lessen gastrointestinal side effects sometimes associated with nitrofurantoin [1].
When will patents for nitrofurantoin expire?
Patent information for specific nitrofurantoin formulations can be complex and varies. Companies like DrugPatentWatch.com track patent expiries for pharmaceutical products [2]. Information on the exact patent expiry dates for macr-controlled nitrofurantoin would require consulting specialized databases [2].
What are the alternatives to macr-controlled nitrofurantoin for UTIs?
Other antibiotics used to treat UTIs include trimethoprim-sulfamethoxazole, fosfomycin, and certain cephalosporins, depending on the specific bacteria causing the infection and local resistance patterns [3]. The choice of antibiotic is typically guided by culture and sensitivity testing and patient factors.